» Articles » PMID: 12618922

Established and Potential Therapeutic Applications of Cannabinoids in Oncology

Overview
Specialties Critical Care
Oncology
Date 2003 Mar 6
PMID 12618922
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Cannabis occurs naturally in the dried flowering or fruiting tops of the Cannabis sativa plant. Cannabis is most often consumed by smoking marihuana. Cannabinoids are the active compounds extracted from cannabis. Recently, there has been renewed interest in cannabinoids for medicinal purposes. The two proven indications for the use of the synthetic cannabinoid (dronabinol) are chemotherapy-induced nausea and vomiting and AIDS-related anorexia. Other possible effects that may prove beneficial in the oncology population include analgesia, antitumor effect, mood elevation, muscle relaxation, and relief of insomnia. Two types of cannabinoid receptors, CB1 and CB2, have been detected. CB1 receptors are expressed mainly in the central and peripheral nervous system. CB2 receptors are found in certain nonneuronal tissues, particularly in the immune cells. Recent discovery of both the cannabinoid receptors and endocannabinoids has opened a new era in research on the pharmaceutical applications of cannabinoids. The use of cannabinoids should be continued in the areas indicated, and further studies are needed to evaluate other potential uses in clinical oncology.

Citing Articles

RNAi Screen Identifies AXL Inhibition Combined with Cannabinoid WIN55212-2 as a Potential Strategy for Cancer Treatment.

Li F, Gong H, Jia X, Gao C, Jia P, Zhao X Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598377 PMC: 11597789. DOI: 10.3390/ph17111465.


Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges.

Faiz M, Naeem F, Irfan M, Aslam M, Estevinho L, Arslan Atessahin D Discov Oncol. 2024; 15(1):490.

PMID: 39331301 PMC: 11436528. DOI: 10.1007/s12672-024-01356-8.


Increased White Matter Coherence Following Three and Six Months of Medical Cannabis Treatment.

Dahlgren M, Gonenc A, Sagar K, Smith R, Lambros A, El-Abboud C Cannabis Cannabinoid Res. 2022; 7(6):827-839.

PMID: 36367574 PMC: 9784607. DOI: 10.1089/can.2022.0097.


Immunohistochemical assessment of cannabinoid type-1 receptor (CB1R) and its correlation with clinicopathological parameters in glioma.

Choucair N, Saker Z, Eddine H, Bahmad H, Fares Y, Zaarour M Pathologica. 2022; 114(2):128-137.

PMID: 35481563 PMC: 9248256. DOI: 10.32074/1591-951X-294.


Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment.

Boullon L, Abalo R, Llorente-Berzal A Front Pharmacol. 2021; 12:734613.

PMID: 34867342 PMC: 8632779. DOI: 10.3389/fphar.2021.734613.